Related Experiment Videos
Amyotrophic lateral sclerosis: lessons in trial design from recent trials
1Department of Neurology, University of Munich, Klinikum Grosshadern, München, Germany. Borasio@lrz.uni-muenchen.de
Journal of the Neurological Sciences
|January 7, 1998
Summary
Clinical trials for amyotrophic lateral sclerosis (ALS) have varied designs, hindering result comparison. This review examines key trial design elements for future ALS drug development.
Area of Science:
- Neurology
- Clinical Trial Design
- Drug Development
Background:
- Recent amyotrophic lateral sclerosis (ALS) clinical trials exhibit significant design heterogeneity.
- This diversity complicates the direct comparison of trial outcomes and efficacy data.
- Ongoing debates focus on essential parameters for evaluating new ALS therapeutics.
Purpose of the Study:
- To critically review and discuss various aspects of clinical trial design in ALS.
- To provide insights into optimizing trial parameters for past, present, and future ALS studies.
- To address challenges in evaluating experimental drugs for ALS.
Main Methods:
- Review of trial design elements including endpoints, progression measures, and quality of life assessments.
- Discussion of placebo-controlled versus open-label trial methodologies.
- Exploration of industry collaboration and methods for investigating drug mechanisms of action.
Main Results:
- Varied trial designs in ALS limit result comparability.
- Key discussion points include endpoint selection, disease progression measurement, and quality of life assessment.
- Consideration of placebo-controlled, open-label trials, and industry collaboration is crucial.
Conclusions:
- Standardizing ALS clinical trial design is essential for advancing drug development.
- Careful selection of endpoints and outcome measures will improve trial interpretability.
- Future trials should incorporate robust methodologies to assess therapeutic efficacy and mechanisms.